, Volume 45, Supplement 3, pp 65–72 | Cite as

Fluoroquinolones: Interaction Profile during Enteral Absorption

  • Karl-Matthias Deppermann
  • Hartmut Lode
State-of-The-Art Presentations


Fluoroquinolones are used worldwide in the treatment of severe infections. These drugs, however, can interact with other agents. This paper is a review of drug interactions with different quinolone derivatives at the absorption phase; the review deals mainly with the prototype quinolones, ciprofloxacin and ofloxacin, and also with some of the newer agents. The concomitant agents considered are food, H2-receptor antagonists, anticholinergic drugs and metallic cationcontaining compounds.

Food (standard breakfast), H2-receptor antagonists and anticholinergic drugs had no major effect on the bioavailability of the quinolones. However, antacids, ferrous sulfate and other metallic cation-containing compounds impaired the bioavailability of the quinolones. This effect is due to chelation between the functional groups of the quinolone molecule and the metallic cations, resulting in insoluble complexes that can not be absorbed. The degree of impairment varied between different quinolone derivatives.


Ranitidine Ofloxacin Ferrous Sulfate Sucralfate Enoxacin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akerele JO, Okhamafe AO. Influence of oral administered metallic cations on ofloxacin pharmacokinetics. Journal of Antimicrobial Chemotherapy 22: 87–94, 1991CrossRefGoogle Scholar
  2. Akerele JO, Okhamafe AO, Chukuka CS. Pharmacokinetic interactions of norfloxacin with some metallic medicinal agents. International Journal of Pharmaceutics 68: 11–18, 1991CrossRefGoogle Scholar
  3. Albert A. Avidity of terramycin and aureomycin for metallic cations. Nature 172: 201, 1953PubMedCrossRefGoogle Scholar
  4. Barr WH, Adir J, Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. Clinical Pharmaceutical Therapeutics 12: 779, 1971Google Scholar
  5. Bauernfeind A. Antimicrobial activity of ciprofloxacin: an overview. In Neu HC, Weuta H, (Eds) First International Ciprofloxacin Workshop. Amsterdam. Excerpta Medica 8: 1–21, 1986Google Scholar
  6. Brouwers JRB. Drug interactions with quinolone antibacterials. Drug Safety 7: 268–281, 1992PubMedCrossRefGoogle Scholar
  7. Brouwers JRB, Van der Kam JH, Sijtsma J, Koks CHW. Important drug interaction of oral ciprofloxacin with sucralfate and magnesium citrate solution. Pharmaceutisch Weekblad — Scientific Edition 11 (Suppl. E): 13–16, 1989Google Scholar
  8. Brouwers JRB, Van Der Kam HJ, Sijtrma J, Proost JH. Important reduction of ciprofloxacin absorption by sucralfate and magnesium citrate solution. Drug Investigation 2: 197–199, 1990aCrossRefGoogle Scholar
  9. Brouwers JRB, Van Der Kam HJ, Sijtrma J, Proost JH. Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. Pharmaceutisch Weekblad — Scientific Edition 12: 182–183, 1990bPubMedCrossRefGoogle Scholar
  10. Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 25: 319–326, 1984PubMedCrossRefGoogle Scholar
  11. Deppermann KM, Lode H, Hüffken G, Tschink G, Kalz G, et al. Influence of ranitidine, pirenzepine and aluminium magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline and amoxicillin-clavulanic-acid. Antimicrobial Agents and Chemotherapy 11: 1901–1907, 1989CrossRefGoogle Scholar
  12. Deppermann K-M, Lode H, Höffken G, Wachter T, Borner K, et al. Influence of food ranitidine and antacids on the enteral absorption of fleroxacin. Journal of Antimicrobial Chemotherapy, submitted, 1993aGoogle Scholar
  13. Deppermann K-M, Lode H, Höffken G, Stuhlert P, Borner K, et al. Influence of ferrous-sulfate on the bioavailability of ciprofloxacin and ofloxacin. European Journal of Microbiology, submitted, 1993bGoogle Scholar
  14. Elwood RJ, Hildebrand PJ, Dundee JW, Collier PS. Ranitidine influences uptake of oral midazolam. British Journal of Clinical Pharmacology 15: 743, 1983PubMedCrossRefGoogle Scholar
  15. Feely J, Guy E. Ranitidine also reduces liver blood flow. Lancet 1: 169, 1982CrossRefGoogle Scholar
  16. Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. Lancet 1: 294, 1986CrossRefGoogle Scholar
  17. Flor S, Guay DP, Opsahl JA, Tack K. Effects of magnesium-aluminium hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrobial Agents and Chemotherapy 12: 2436–2438, 1990CrossRefGoogle Scholar
  18. Foster T, Blouin R. The effectof an antacid timing on lomefloxacin bioavailability. Pharmacotherapy 11: 101, 1991Google Scholar
  19. Garrelts JC, Godlwey PJ, Peterie JD, Gerlach EH, Yakshe CC. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrobial Agents and Chemotherapy 5: 931–933, 1990CrossRefGoogle Scholar
  20. Golper TA, Hartstein AI, Morthland VH, Christensen JM. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 31: 1787–1790, 1987PubMedCrossRefGoogle Scholar
  21. Gothoni G, Neuvonen PJ, Mattila M, Hackman R. Iron-tetracycline interaction: effect of time interval between the drugs. Acta Medica Scandinavica 191: 409–411, 1972PubMedGoogle Scholar
  22. Grasela Jr TH, Schentag JJ, Sedman AJ, Wilton JH, Thomas DJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrobial Agents and Chemotherapy 33: 615–617, 1989PubMedCrossRefGoogle Scholar
  23. Gyr K, Meier R. Stressulkuskrankheit und deren Prophylaxe. Schweizerische Medizinische Wochenschrift 119: 423–429, 1989PubMedGoogle Scholar
  24. Hoensch H, Hutzel H, Kirch W, Ohnhaus EE. Isolation of human hepatic microsomes and their inhibition by cimetidine and ranitidine. European Journal of Clinical Pharmacology 29: 199–206, 1984CrossRefGoogle Scholar
  25. Höffken G, Borner K, Glatzel PD, Koeppe P, Lode H. Reduced enterai absorption of ciprofloxacin in the presence of antacids. European Journal of Clinical Microbiology 3: 345, 1985CrossRefGoogle Scholar
  26. Höffken G, Lode H, Wiley R, Glatzel P-D, Sievers B, et al. Pharmacokinetics and interaction in the bioavailability of new quinolones. International Symposium on New Quinolones, July 17–19, Abstract No. 071, Geneva, Switzerland, 1986Google Scholar
  27. Höffken G, Lode H, Prinzing C, Borner K, Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrobial Agents and Chemotherapy 9: 1338–1342, 1987Google Scholar
  28. Höffken G, Lode H, Wiley R, Glatzel D, Sievers B, et al. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effects of food and antacid intake. Reviews of Infectious Diseases 10 (Suppl. 1): S138–S139, 1988CrossRefGoogle Scholar
  29. Jaehde U, Sörgel F, Koch HU, Stephan U, Gottschalk B, et al. Gastrointestinal and hepatic drug interactions with pefloxacin, a new quinolone. Clinical Pharmacology and Therapeutics 41 (2): 166, 1987Google Scholar
  30. Kara M, Hasinoff BB, McKay DW, Campbell NRC. Clinical chemical interactions between iron preparations and ciprofloxacin. Abstract. British Journal of Clinical Pharmacology 31: 257–261, 1991CrossRefGoogle Scholar
  31. Kemmerich B, Small GJ, Pennington JE. Comparative evaluation of ciprofloxacin, enoxacin and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. Antimicrobial Agents and Chemotherapy 29: 395–399, 1986PubMedCrossRefGoogle Scholar
  32. Kirch W, Hoensch H, Janisch HD. Interactions and non-interactions with ranitidine. Clinical Pharmacokinetics 9: 493–510, 1984PubMedCrossRefGoogle Scholar
  33. Koch-Weser J. Bioavailability of drugs, part 1 and 2. New England Journal of Medicine 291: P 233–237; 503–508, 1974PubMedCrossRefGoogle Scholar
  34. Lederer PCH, Lux G. Motilitätsbeeinflussende Medikamente in der Ulkustherapie. Zeitschrift für Gastroenterologie (Suppl. 3): 25: 175–180, 1987Google Scholar
  35. Ledergerber B, Bettex JD, Joos B, Flepp M, Lüthy R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrobial Agents and Chemotherapy 27: 350–352, 1985PubMedCrossRefGoogle Scholar
  36. Lelaiche J, Catton D, Zittonn J, Marguet J, Yvart J. Effect of ranitidine on cobalamin absorption. Digestive Diseases and Sciences 28: 667, 1983Google Scholar
  37. Lode H, Hüffken G, Olschewski P, Sievers B, Kirch A, et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrobial Agents and Chemotherapy 31: 1338–1342, 1987PubMedCrossRefGoogle Scholar
  38. Lode H. Drug interactions with quinolones. Reviews of Infectious Diseases 10: 5132–5136, 1988CrossRefGoogle Scholar
  39. Lomaestro BM, Bailie GR. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrobial Agents and Chemotherapy 5: 1004–1007, 1991CrossRefGoogle Scholar
  40. Masoero G, Rossanino A, Arossa W, Marchetto M, Marucci M, et al. Daily gastric pH in controls and in duodenal ulcer patients: basal condition and response to treatment. American Journal of Gastroenterology 83: 136–142, 1988PubMedGoogle Scholar
  41. Neuvonen PJ, Gothoni G, Hackman R, Bjärksten K. Interference of iron with the absorption of tetracyclines in man. British Medical Journal 4: 532–534, 1970PubMedCrossRefGoogle Scholar
  42. Neuvonen PJ, Pentikainen PJ, Gothone G. Inhibition of iron absorption by tetracycline. British Journal of Clinical Pharmacology 2: 94–96, 1975PubMedGoogle Scholar
  43. Neuvonen PJ, Pentilla O. Effect of oral ferrous sulphate on the half life of doxycycline in man. European Journal of Clinical Pharmacology 7: 361, 1974PubMedCrossRefGoogle Scholar
  44. Neuvonen PJ, Turakka H. Inhibitory effect of various iron salts on the absorption of tetracyclines in man. European Journal of Clinical Pharmacology 7: 357–360, 1974PubMedCrossRefGoogle Scholar
  45. Nix DE, Watson WA, Handy L, Frost RW, Rescott DL. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy 9: 377–380, 1989aPubMedGoogle Scholar
  46. Nix DE, Watson WA, Lerner ME, Frost RW, Krol G, et al. Effects of aluminium and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clinical Pharmacology and Therapeutics 46: 700–705, 1989bPubMedCrossRefGoogle Scholar
  47. Nix DE, Wilton JH, Ronald B, Linda Distlerath L, Williams VC, et al. Inhibition of norfloxacin absorption by antacids. Antimicrobial Agents and Chemotherapy 3: 432–435, 1990CrossRefGoogle Scholar
  48. Norris A, Mandell GL. The quinolones. History and overview. (Andriole VT, Ed.) Academic Press Limited, 1–22, 1988Google Scholar
  49. Parpia S, Nix DE, Linda G, Hejmanowski H, Goldstein R, et al. Sucralfate reduces the gastrointestinal absorption or norfloxacin. Antimicrobial Agents and Chemotherapy 33: 99–102, 1989PubMedCrossRefGoogle Scholar
  50. Polk RE, Healy DP, Sahai JV, Drwal L, Pracht E. Effect of ferrous sulfate and multivitamins with zinc on the absorption of ciprofloxacin in normal volunteers. Antimicrobial Agents and Chemotherapy 11: 1841–1844, 1989CrossRefGoogle Scholar
  51. Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner M. Ciprofloxacin and antacids. Lancet 1: 48, 1986CrossRefGoogle Scholar
  52. Schentag JJ, Watson WA, Nix DE, Sedman AJ, Frost RW. Time dependent interactions between antacids and quinolone antibiotics. Clinical Pharmacology and Therapeutics 43: 135, 1988Google Scholar
  53. Shiba K, Saito A, Shimada J, Hor S, Kaji M. Interactions of fleroxacin with dried aluminium hydroxide gel and probenecid. Reviews of Infectious Diseases 11 (Suppl. 5): 18–19, 1989Google Scholar
  54. Shishido H, Matsumoto K, Nagatake T, Tabuchi S. Cross-over pharmacokinetics of NY-198 and ofloxacin in healthy volunteers and gastrectomized patients. Chemotherapy 36 (Suppl. 2): 256–264, 1988Google Scholar
  55. Soffer EE, Kumar D, Mridha K, DasGupta A, Britto J, et al. Effect of pirenzepine on oesophageal, gastric and enteric motor function in man. Scandinavian Journal of Gastroenterology 23: 146–150, 1989CrossRefGoogle Scholar
  56. Smith JT. Awakening the slumbering potential of the 4-quinolone antibacterials. Pharmaceutical Journal 233: 299–305, 1984Google Scholar
  57. Smith SR, Kendall MJ. Ranitidine versus cimetidine. A comparison of their potential to cause clinical important drug interactions. Clinical Pharmacokinetics 15: 44–46, 1988Google Scholar
  58. Somogyi AA, Bochner F, Keal JA, Rolan PE, Smith M. Effect of food on enoxacin absorption. Antimicrobial Agents and Chemotherapy 4: 638–639, 1987CrossRefGoogle Scholar
  59. Spahn HE, Mutschler W, Kirch W, Ohnhaus EE, Janisch HD. Influence of ranitidine on plasma metoprolol and atenolol concentrations. British Medical Journal 286: 1546, 1983PubMedCrossRefGoogle Scholar
  60. Stacher G, Havlik E, Bergmann H, Schmierer G, Sinklehner S. Effects of oral pirenzepine on gastric emptying and antral motor activity in healthy man. Scandinavian Journal of Gastroenterology 17 (Suppl. 72): 153–158, 1982Google Scholar
  61. Timmers K, Sternglanz R. Scheinbare Dissoziationskonstanten. Bioorganic Chemistry 9: 145–155, 1978Google Scholar
  62. Tryba M, Zevounou F, Wruck G. Streβblutungen und postoperative Pneumonien bei intensivpatienten unter Ranitidin oder Pirenzepin. Deutsche Medizinische Wochenschrift 113: 930–936, 1988PubMedCrossRefGoogle Scholar
  63. Tsuji AE, Nakashima S, Hamano TY. Physiochemical properties of amphoteric beta lactam antibiotics I: stability, solubility and dissolution behaviour of amino-penicillins as a function of pH. Journal of Pharmaceutical Sciences 67: 1059–1066, 1978PubMedCrossRefGoogle Scholar
  64. Van Slooten AD, Nix DE, Wilton JH, Love JH, Spivey JM. Combined use of ciprofloxacin and sucralfate. DICP: Annals of Pharmacotherapy 25: 578–581, 1991PubMedGoogle Scholar
  65. Walt RP, Male PJ, Rawlings J, Hunt RH, Misiewicz JJ. Comparison of the effects of ranitidine, cimetidine and placebo on the 24 hour intragastric acidity and nocturnal secretion in patients with duodenal ulcer. Gut 22: 49, 1981PubMedCrossRefGoogle Scholar
  66. Weinberg ED. The mutual effects of antimicrobial compounds and metallic cations. Bacteriological Reviews 21: 24–68, 1957Google Scholar
  67. Welling PG. Interactions affecting drug absorption. Clinical Pharmacokinetics 9: 404–434, 1984PubMedCrossRefGoogle Scholar
  68. Wingender W, Forster D, Beermann D, Rohwedder R, Graefe KH, et al. Effect of the gastric emptying time on rate and extent of the systemic availability of ciprofloxacin (BAY o 9867) in humans. Proceedings Chemiotherapia 4 (Suppl. 2): 1585–1586, 1985Google Scholar
  69. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanism of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy 28: 581–586, 1985PubMedCrossRefGoogle Scholar
  70. Yuk JH, Nightingale CN, Quintiliani R. Ciprofloxacin levels when receiving sucralfate. Journal of the American Medical Association 262: 901–904, 1989PubMedCrossRefGoogle Scholar

Copyright information

© ADIS International Limited 1993

Authors and Affiliations

  • Karl-Matthias Deppermann
    • 1
  • Hartmut Lode
    • 2
  1. 1.Medical Department, Klinikum SteglitzFreie Universität BerlinBerlin 45Germany
  2. 2.Department of Pulmonary and Infectious DiseasesCity Hospital Berlin-ZehlendorfBerlinGermany

Personalised recommendations